Skip to main content

Table 1 Patient and tumor characteristics by molecular subtype

From: Locoregional therapy in luminal-like and HER2-enriched patients with de novo stage IV breast cancer

  Luminal-like HER2 -rich Triple negative p
  (n = 121, 49.2%) (n = 80 , 32.5%) (n = 45, 18.3%)  
Age
  > 40 94 (77.7%) 67(83.8%) 36 (80%) 0.5739
  ≤ 40 27 (22.3%) 13(16.2%) 9 (20%)  
Menopause status
  Premenopausal 81 (66.9%) 30(37.5%) 22 (48.9%) 0.0002
  Postmenopausal 40(33.1%) 50(62.5%) 23(51.1%)  
Primary tumor size
  cT1-3 56(46.3%) 36(45.0%) 23(51.1%) 0.7974
  cT4 65(53.7%) 44(55.0%) 22(48.9%)  
Nuclear grade
  Nuclear Grade 1-2 24(19.8%) 9(11.3%) 1(2.2%) 0.0092*
  Nuclear Grade 3 35 (28.9%) 28(35.0%) 18 (40.0%)  
  unknown 62(51.3%) 43(53.7%) 26(57.8%)  
Lymphovascular invasion
  No / Focal 15(12.4%) 14(17.5%) 5(11.1%) 0.22121*
  prominent 30(24.8%) 12(15.0%) 9(20.0%)  
  unknown 76(62.8%) 54(67.5%) 31(68.9%)  
Lymph node status
  No axillary LN involvement 30 (24.8%) 19(23.8%) 8 (17.8%) 0.6284
  Axillary, IM, or SC LN involvement 91(75.2%) 61(76.2%) 37(82.2%)  
Tumor markers
  Elevated CEA 53 (43.8%) 40(50.0%) 15 (33.3%) 0.2740*
  Elevated CA 15-3 71 (58.7%) 34(42.5%) 18 (40.0%) 0.0063
Metastasis site at first diagnosis
  Liver 27 (22.3%) 43(53.8%) 18 (40%) < 0.0001
  Lung 42 (34.7%) 34(42.5%) 18 (40%) 0.5189
  Brain 15(12.4%) 13(16.3%) 8(17.8%) 0.6041
  Bone 95 (78.5%) 53(66.3%) 26 (57.8%) 0.0187
Treatments
  Systemic chemotherapy 106 (87.6%) 76(95.0%) 37 (82.2%) 0.0705
  Anti-hormonal treatment 24 (19.8%) 6(7.5%) 1 (2.2%) 0.0024
  Local treatment to primary breast tumor 62(51.2%) 33(41.3%) 18(40.0%) 0.2571
  1. *About whom information was known.